Premium
Prognostic significance of hormone receptors in endometrial cancer
Author(s) -
Creasman William T.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.2820710411
Subject(s) - medicine , endometrial cancer , hormone receptor , oncology , malignancy , estrogen receptor , stage (stratigraphy) , cancer , proportional hazards model , progesterone receptor , carcinoma , gynecology , disease , hormone , breast cancer , biology , paleontology
Background . Endometrial carcinoma is the most common femalé pelvic genital malignancy. Many studies suggest that approximately 75% of all endometrial cancers are clinical Stage I. More than 50% of cancer deaths are in patients with clinical Stage I disease. As a result, prognostic factors have been evaluated in an attempt to identify those patients with presumed early stage disease who will be at high risk for recurrence. Recently, hormone receptor status (estrogen [ER], progesterone [PR]) in endometrial cancer has been suggested to be a prognostic factor. Methods . Two hundred seventeen patients with Stage I and II endometrial cancers were evaluated for cytoplasmic steroid‐receptor status. These results were compared with other prognostic factors in both univariant and multivariant analysis. Results . When ER and PR and combined ER/PR status were analyzed separately, patients with receptor‐positive lesions had significantly better disease‐free survival than those with receptor‐negative lesions. The receptor status was also a significant independent prognostic factor when evaluated by stepwise proportional hazards regression analysis. Conclusions . Hormone receptor status in endometrial cancer appears to be an important prognostic factor.